Investigational Drug Details
| Drug ID: | D391 |
| Drug Name: | VSL#3 |
| Synonyms: | -- |
| Type: | Biological drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 742088-29-5 |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | TCPTP activator |
| Therapeutic Category: | Probiotics |
| Clinical Trial Progress: | Phase 1&2 terminated (NCT03511365: IRB haulted the study there was no evidence that the probiotic would benefit the patient) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0089 | NCT03511365 | Phase 1/Phase 2 | Terminated | No Results Available | May 15, 2018 | January 7, 2020 | Details |
| L0357 | NCT00099723 | Phase 1 | Terminated | No Results Available | October 2004 | February 11, 2010 | Details |
| L0802 | CTRI/2017/12/010997 | Phase 1 | Not Recruiting | No Results Available | 27/12/2017 | 24 November 2021 | Details |
| L0933 | ISRCTN05474560 | Not applicable | Not Recruiting | No Results Available | 09/08/2012 | 17 October 2016 | Details |
| L0974 | CTRI/2008/091/000074 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 09/06/2008 | 24 November 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A03999 | 33794784 | BMC Gastroenterol | A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. | Details |
| A13227 | 30074574 | J Pediatr Gastroenterol Nutr | Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. | Details |
| A20675 | 25809828 | Int J Obes (Lond) | Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. | Details |
| A22228 | 24738701 | Aliment Pharmacol Ther | Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. | Details |
| A22627 | 24400795 | Immunology | Probiotic antigens stimulate hepatic natural killer T cells. | Details |
| A27027 | 19321579 | J Nutr | Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. | Details |
| A27137 | 19115316 | Hepatology | VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. | Details |
| A28256 | 15942443 | J Clin Gastroenterol | Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. | Details |
| A28494 | 12540784 | Hepatology | Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. | Details |
| A30489 | 32355675 | Hepatobiliary Surg Nutr | Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. | Details |
| A34631 | 23029000 | PLoS One | VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. | Details |
| A43580 | 31356353 | Curr Opin Pediatr | The good bugs: the use of probiotics in pediatrics. | Details |
| A49627 | 35685888 | Front Nutr | Probiotic Therapy With VSL#3® in Patients With NAFLD: A Randomized Clinical Trial. | Details |